Toward Risk-Benefit Assessments in Psychedelic- and MDMA-Assisted Therapies JAMA Psychiatry April 27, 2022 Mazdak M. Bradberry, Natalie Gukasyan, Charles L. Raison 20 citations No Summary DOI: 10.1001/jamapsychiatry.2022.0665 Full text Otorhinolaryngology Neurology Family medicine Psychiatry